WASHINGTON UNIVERSITY PAUL CALABRESI CAREER DEVELOPMENT AWARD FOR CLINICAL ONCOLO

描述（由申请人提供）：测序技术和生物信息学的进步现在使得前所未有地全面研究癌症基因组的复杂景观成为可能。新的靶点正在被确定，仅仅根据显微镜发现对癌症亚型进行分类的传统方法正在让位于分子基因分型。如今，从事以患者为导向的癌症研究的研究人员需要善于将基因组分析中迅速出现的数据转化为临床数据。此外，临床研究人员应接受充分培训，以评估用于诊断和治疗的各种模式的相对有效性，以优化临床实践并控制飙升的医疗保健费用。我们正在申请Paul Calabresi临床肿瘤学职业发展奖，以通过培训下一代精通当今以患者为导向的癌症研究的三个关键领域的临床研究人员来实现这些目标：癌症基因组学，转化医学/临床试验和比较有效性研究。 我们建议利用华盛顿大学（WU）的特殊资源，包括基因组学研究所，Siteman癌症中心，临床研究培训中心和公共卫生研究所，以培训为该计划选择的个人。WU临床肿瘤学（K12）Paul Calabresi职业发展计划的广泛目标是培养新一代具有专业知识的高技能研究人员，他们将为在这个激动人心的时期领导癌症研究做好充分准备，并从癌症基因组学中获得新兴的信息。在这些优先事项中，我们将把培训重点放在三个关键领域，1）癌症基因组学，生物信息学，分析及其在以患者为导向的研究中的应用，2）转化医学，特别强调将快速出现的基因组数据转化为临床，临床试验设计，执行和分析，在这个个性化治疗的时代和3比较有效性研究。为了促进这一点，PC学者将选择WU PC CDP提供的三个选修课程之一：癌症基因组学课程，转化医学/临床试验者课程和CER课程。我们建议与CTSA和WU的其他职业发展计划开发和领导协作学习网络，以分享最佳实践和知识，并传播WU临床肿瘤学K12计划之外的新培训计划和课程，以扩大该计划的影响。从该计划中受益的WU PC学者和其他研究人员将学习进行研究，这些研究将提供新的信息，以解决当前的证据差距，以及如何将这些知识转化为癌症患者预后的改善。

DESCRIPTION (provided by applicant): Advances in sequencing technologies and bioinformatics have now made it possible to study comprehensively the complex landscape of the cancer genome as never before. Novel targets are being identified and conventional methods of categorizing cancer subtypes merely based on the microscopic findings are giving way to molecular genotyping. Investigators engaged in patient oriented cancer research today need to be adept in translating the rapidly emerging data from genomic analyses to the clinic. Furthermore, clinical investigators should be adequately trained to assess the comparative effectiveness of various modalities used for diagnosis and therapy to optimize clinical practice and contain the soaring health care costs. We are applying for the Paul Calabresi Career Development Award for Clinical Oncology to achieve these goals by training the next generation of clinician-investigators well versed in the three key areas relevant to patient oriented cancer research today: Cancer Genomics, Translational Medicine/Clinical Trials and Comparative Effectiveness Research. We propose to use the exceptional resources at Washington University (WU) including The Genomics Institute, Siteman Cancer Center, Clinical Research Training Center and Institute for Public Health to train the individuals selected for this program. The broad goal of the WU Clinical Oncology (K12) Paul Calabresi Career Development Program is to train a new generation of highly skilled investigators with specialized expertise who will be well prepared to lead cancer research during this exciting period with the emerging body of information from cancer genomics. Within these priorities we will focus our training in three key areas, 1) Cancer genomics, bioinformatics, analysis and their application in patient oriented research, 2) Translational Medicine with special emphasis on translating rapidly emerging genomic data to the clinic, clinical trial design, execution and analysis in this era of personalized therapy and 3 Comparative Effectiveness Research. To facilitate this, PC scholars will choose one of the three elective tracks offered by the WU PC CDP: Cancer Genomics track, Translational Medicine/ Clinical Trialist track and CER track. We propose to develop and lead collaborative learning networks with the CTSAs and other career development programs at WU to share best practices and knowledge and disseminate new training programs and curricula beyond WU Clinical Oncology K12 Program to broaden the impact of this program. WU PC scholars and other investigators benefitting from this program will learn to perform research that will provide new information addressing current evidence gaps and how to translate this knowledge into improvements in the outcomes of patients with cancer.